Comprehensive lung cancer care — from early screening of pulmonary nodules to advanced-stage immunotherapy and targeted therapy, delivered by a multidisciplinary team of thoracic surgeons, medical oncologists, radiation oncologists, and interventional pulmonologists.
From the first detection of a pulmonary nodule to the most advanced stage of lung cancer, our center provides seamless, coordinated care at every step.
Pulmonary nodule screening → diagnosis → treatment → survivorship
The Lung Cancer Center at Beijing Arion Cancer Hospital addresses the full continuum of lung cancer care. Our journey begins with early screening and risk assessment of pulmonary nodules — using AI-assisted imaging analysis to distinguish benign from suspicious lesions, ensuring that patients receive timely intervention without unnecessary procedures.
For diagnosed lung cancer, our MDT team — comprising thoracic surgery, medical oncology, radiation oncology, and interventional pulmonology — collaborates to develop a personalized treatment plan. Early-stage patients may benefit from minimally invasive surgical resection (VATS or robotic-assisted), while advanced-stage patients access the latest targeted therapies, immunotherapy (PD-1/PD-L1 checkpoint inhibitors), and precision radiation techniques including SBRT and IMRT.
Our interventional pulmonology program offers advanced diagnostic and therapeutic procedures including navigational bronchoscopy, endobronchial ultrasound (EBUS), and radiofrequency ablation — providing minimally invasive options for diagnosis and localized treatment. Throughout the journey, the MDT team meets regularly to assess treatment response and adjust the plan in real time.
Four core specialties, one coordinated team — ensuring that every lung cancer patient benefits from multidisciplinary expertise at every decision point.
Our thoracic surgeons specialize in minimally invasive approaches — video-assisted thoracoscopic surgery (VATS) and robotic-assisted resection — for lung cancer. These techniques reduce postoperative pain, shorten hospital stay, and accelerate recovery while achieving complete oncologic resection. Sublobar resection, lobectomy, and sleeve resection are tailored to tumor location and stage.
Our medical oncologists deliver systemic therapy tailored to the tumor's molecular profile. This includes targeted therapy for EGFR mutations, ALK rearrangements, ROS1, and other driver mutations, as well as immunotherapy with PD-1/PD-L1 checkpoint inhibitors. Chemotherapy regimens follow the latest international guidelines, with neoadjuvant and adjuvant strategies integrated into the MDT plan.
Advanced radiation therapy options include Stereotactic Body Radiation Therapy (SBRT) for early-stage inoperable tumors and oligometastatic disease, and Intensity-Modulated Radiation Therapy (IMRT) for precisely targeting tumors while sparing surrounding healthy tissue. Our radiation oncologists work with the MDT team to integrate radiation into the overall treatment sequence.
Our interventional pulmonologists provide minimally invasive diagnostic and therapeutic procedures. Navigational bronchoscopy and EBUS-TBNA enable precise tissue sampling for molecular testing. Radiofrequency ablation (RFA) offers a localized treatment option for patients who are not surgical candidates, while airway stenting and debulking relieve symptoms in advanced cases.
A comprehensive arsenal of lung cancer treatments, from minimally invasive surgery to cutting-edge systemic and localized therapies.
Video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery for lung cancer. Minimally invasive approaches with smaller incisions, faster recovery, and comparable oncologic outcomes to open surgery.
Precision medicine targeting EGFR mutations, ALK rearrangements, ROS1, BRAF, KRAS G12C, and other driver mutations. Molecular testing guides the selection of tyrosine kinase inhibitors and other targeted agents.
PD-1 and PD-L1 immune checkpoint inhibitors that activate the patient's own immune system to fight cancer. Used as monotherapy or combined with chemotherapy, guided by PD-L1 expression and tumor mutational burden.
Evidence-based chemotherapy regimens for neoadjuvant, adjuvant, palliative, and combination settings. Platinum-based doublets and newer agents, integrated with targeted and immunotherapy within the MDT plan.
Stereotactic Body Radiation Therapy (SBRT) for early-stage and oligometastatic disease, and Intensity-Modulated Radiation Therapy (IMRT) for conformal treatment. Precise targeting with minimal damage to healthy lung tissue.
Image-guided radiofrequency ablation for localized tumor destruction — an option for patients who cannot undergo surgery, or for treating recurrent or metastatic lesions with minimal invasiveness.
Our Lung Cancer Center is led by specialists from China's premier cancer and respiratory medicine institutions, bringing deep expertise in medical oncology and respiratory care.
A highly respected lung cancer specialist from Beijing Chest Hospital, Dr. Zhang is a leading authority in thoracic medical oncology. With decades of clinical experience dedicated to lung cancer treatment, he has deep expertise in chemotherapy, targeted therapy, and immunotherapy for all stages of lung cancer. He is known for his contributions to lung cancer clinical research and his commitment to bringing the latest evidence-based treatments to his patients.
From the Respiratory Medicine department of the PLA General Hospital, Dr. Gao brings extensive experience in respiratory and thoracic diseases with a specialization in lung cancer. His expertise spans the diagnostic workup of pulmonary nodules, interventional pulmonology procedures, and the medical management of lung cancer. He plays a key role in the MDT team's evaluation of complex pulmonary cases.
Early detection is the most powerful weapon against lung cancer. Our screening program identifies and risk-stratifies pulmonary nodules for timely intervention.
Low-dose CT screening combined with AI-powered nodule detection and characterization. Our AI model analyzes nodule size, morphology, density, and growth patterns to calculate malignancy risk — helping distinguish benign from suspicious nodules with high accuracy.
Suspicious nodules are tracked with structured follow-up protocols based on international guidelines (Fleischner, Lung-RADS). Our team monitors nodule growth and characteristics over time, ensuring that malignant nodules are identified and treated at the earliest possible stage.
When a nodule requires further evaluation, our MDT team reviews the imaging, patient history, and risk factors together. This collaborative assessment determines whether to monitor, biopsy, or proceed directly to treatment — with the full team's consensus guiding every decision.